Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 K660N |
Therapy | Fexagratinib + Fulvestrant |
Indication/Tumor Type | breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 K660N | breast cancer | sensitive | Fexagratinib + Fulvestrant | Preclinical - Cell culture | Actionable | In a preclinical study, AZD4547 and Faslodex (fulvestrant) combination treatment decreased viability of ESR1-positive breast cancer cells expressing FGFR2 K660N in culture (PMID: 32723837). | 32723837 |
PubMed Id | Reference Title | Details |
---|---|---|
(32723837) | Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. | Full reference... |